The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome

New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome

July 18, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

anyaivanova_Shutterstock_GenericLabTech_500x270Physicians use three tests to detect antiphospholipid antibodies (aPL) and diagnose antiphospholipid syndrome (APS). Two of these tests are enzyme-linked immunosorbent assays (ELISAs) that measure IgG and IgM anti-cardiolipin (aCL) and anti-β2-glycoprotein (aβ2GPI). The third test is a functional clotting assay for lupus anticoagulant (LA). A new study has found that measuring additional antibodies to β2GPI may improve the diagnosis of APS. In particular, measurement of IgG Domain I (aDI) of β2GPI, IgA aβ2GPI and IgA aDI may be helpful in the management of APS in general, and thrombotic APS in particular.

You Might Also Like
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome
  • Antiphospholipid Syndrome
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
Also By This Author
  • Lyme Disease Spreads Through Ontario

Charis Pericleous, PhD, postdoctoral researcher at the University College London in the U.K., and colleagues published the results of their observational, multicenter cohort study June 2 in PLOS ONE. They tested patients for IgG, IgM and IgA activity against β2GPI, DI and CL.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In this study, we performed nine different assays using sera from 430 subjects,” explain the authors in their article. “This large dataset allows the first rigorous comparison of IgG, IgM and IgA aCL, aβ2GPI and aDI in patients with APS, SLE and healthy controls. We confirm the importance of IgG aCL and IgG aβ2GPI tests, which had the highest sensitivity for APS and were strongly associated with LA positivity.”

Additionally, although all of the tested assays had good specificity for APS, the investigators found that patients who tested positive for IgA aβ2GPI had a higher hazard ratio for APS when compared with patients who tested positive for IgM aβ2GPI. They also note that, although IgG aβ2GPI has been well studied, the role of IgA aβ2GPI in pathogenicity is less well understood. Their finding that a positive test for IgG, IgM or IgA aDI was each associated with APS is consistent with a previous study that documented an added value in measuring IgG aDI, as well as aCL/aβ2GPI for the identification of patients who are at increased risk for vascular thrombosis (VT). Reinforcing this finding, the current study also found that IgG aCL, aβ2GPI, aDI and IgA aDI were all associated with thrombotic, but not obstetric, complications in patients with APS.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“In line with recently published studies, we also found that aDI were more common in APS patients who were aCL, aβ2GPI and LA positive,” add the authors. Specifically, individuals who tested positive for aCL and/or aβ2GPI had a three- to five-fold increased hazard ratio for APS if they were also positive for aDI. The researchers conclude, “Based on our current findings and other groups’ published reports, we consider aDI tests as a useful additional test rather than a replacement for tests using whole β2GPI, since the latter would also pick up aβ2GPI directed against other domains.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Antibodies, Antiphospholipid Syndrome, APS, assay

You Might Also Like:
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome
  • Antiphospholipid Syndrome
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
  • Is Hydroxychloroquine Helpful for Patients with Antiphospholipid Syndrome?

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.